

## Curriculum vitae



**Name:** ALAA FADHIL ALWAN

**Sex:** male

**Place & date of birth:** IRAQ – DIYALA-Alkhalis / 11 August 1973

**Nationality:** Iraqi

**Marital status:** Married, 3 babies

**E-mail:** ala\_sh73@yahoo.com

**Languages:**

1. Arabic
2. English

**Qualifications:**

1. Fellow of Iraqi board for medical specialization in internal medicine
2. Fellow of Iraqi board for medical specialization in adult clinical hematology
3. Certificate of competence in lymphoma
4. Diploma in lymphoma from Ulm university/ Germany
5. M.B.Ch.B from Tikrit University College of medicine.

**Employment history:**

1. February 2015 promotion to consultant in adult clinical hematology
2. October 2014 promotion to professor degree in adult clinical hematology
3. October 2012 to September 2019 : director of the national center of hematology at Almustansiriya university
4. May 2009 to October 2014: Assistant professor of clinical hematology / Almustansiriya university/ college of medicine
5. May 2009 to February 2015: senior hematologist at the National center of hematology/ Almustansiriya university
6. Feb. 2005 to May 2009: Instructor / Tikrit University College of medicine Department of medicine
7. from Oct. 2005 to May 2009: Attending physician /Hematology unit / Baghdad Teaching hospital
8. from 2000-2004 joined the training programme of Iraqi Board in internal Medicine as senior house officer / Baghdad Teaching Hospital.
9. from 1999-2000 lecturer at Tikrit University College of Medicine /Department of medicine
8. from 1997-1999 junior resident / Medical city hospital.

**Activities & knowledge:**

1. Active member of Iraqi Medical Association since 1997 till now
2. Active member of European Hematology Association (EHA) since 2008 till now
3. Active member of European school of oncology since 2007 till now
4. Active member of international society of hematology since 2010 till now
5. Active member of international society of hemostasis and thrombosis since 2017 till now
6. Active member of British society of hematology since January 2020

7. Active member of International academy for clinical hematology since march 2020
8. Regular participant in the educational programs of EHA, ESO, and ASH.
9. Interested in clinical Hemato-oncology and bone marrow transplant
10. Editor in chief of Iraqi journal of hematology since 2012 till now

**Research works:**

***Published***

1. Serum lactate dehydrogenase level in non-Hodgkin's lymphoma: relationship to certain features at time of diagnosis. Tikrit Med.J. Vol.13, no.2, 2007, p32-38
2. Serum Lactate Dehydrogenase Level in Acute Leukemias. J. of Baghdad Medical Faculty, vol. 49, no.4, 2007, p 369-74.
3. Acute Transformation in Chronic Myelogenous Leukemias. Tikrit Med. J. Vol. 13, no.1, 2007, p 12-17.
4. acute myeloid leukemia : clinical features and follow-up of 115 Iraqi patients admitted to Baghdad Teaching hospital.Tikrit Med. J.vol 15.no.1.p1-8
5. Impact of switching therapy from imatinib mesylate to generic copy of imatinib on hematologic response in patients with chronic phase chronic myeloid leukemia: sin... (abstract) EHA 2011
6. Efficacy of ceftazidime plus amikacin as an initial empirical therapy for adult patients with febrile neutropenia.int j sci tech.jordan.2012 july
7. PCN72 Modeling the Survival Loss in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Phase Chronic Myeloid Leukemia (CML-CP) Switched from Imatinib Mesylate to a Generic Copy. Value in Health 15(7):A422 · November 2012 DOI: 10.1016/j.jval.2012.08.2112
8. Assessment of Clinical Safety and Estimate of Survival in Iraqi Patients with Chronic Myeloid Leukemia Switched From Glivec (β-Crystalline Form of Imatinib Mesylat...M Botteman, M Magestro, AF Alwan, PW Manley, O Zernovak, ...Blood 120 (21), 4439-4439
9. The efficacy of fludarabine, high dose cytosine arabinoside with granulocyte colony stimulating factor (FLAG) protocol as salvage therapy for refractory/relapsed acute leukemias in adult Iraqi patients. Indian Journal of Hematology and Blood Transfusion.February 2013
10. Study of Plasma fibrinogen in pregnant women with severe preeclampsia. IOSR Journal of Dental and Medical Sciences.Volume 8, Issue 5 (Jul.- Aug. 2013), PP 55-59
11. Outcome of 50 Iraqi patients with acute lymphoblastic leukemia treated by modified German multicenter study group (GMALL) protocol.journal of Almustansiriya medical college.
12. Evaluation of the Safety of Imatinib Mesylate in 200 Iraqi Patients with Chronic Myeloid Leukemia in the Chronic Phase: Single-Center Study. Turk J Hematol. 2013; 30(4): 387-393 | DOI: 10.4274/Tjh.2012.0135
13. Assessment of the efficacy and safety of intravenous iron sucrose in treatment of adult patients with iron deficiency anemia. community medicine.2013
14. Prospective single-center study of chronic myeloid leukemia in chronic phase: switching from branded imatinib to a copy drug and back  
More: <http://informahealthcare.com/doi/abs/10.3109/10428194.2014.904508>
15. Efficacy and Tolerance of Fludarabine and Cyclophosphamide (FC) Combination Regimen in advance stage of Chronic Lymphocytic Leukemia. J Med J 2013; December: Vol. 47 (4) <http://dar.ju.edu.jo/jmj>

16. Incidence of von Willebrand disease among patients presenting with various bleeding tendency to out-patient clinic of the national center of hematology. Iraqi journal of hematology vol 2 issue1.
17. Incidence of hepatitis G virus in patients with hematological malignancies with repeated blood transfusion. Indian Journal of Medicine and Healthcare Vol: 2 Issue: 5 May .2013 ISSN: 2278-2966 pp 259-262
18. Assessment of cytogenetic response . with imatinib mesylate in patients with chronic phase chronic myeloid leukemia. Iraqi journal of hematology.vol.2.issue 1
19. Incidence of Epstein Barr Virus infection in newly diagnosed non-Hodgkin lymphoma in the national center of hematology-single center study. Iraqi Journal of Cancer and Medical Genetics. 2014.Volume 7 - Number 1
20. Evaluation of Electrolytes in Adult Patients with Acute Leukemia before and after Chemotherapy. J. Baghdad for Sci. Vol.10(2)2013
21. Survival of patients with multiple myeloma diagnosed at the national center of hematology in Baghdad. Iraqi Journal of Cancer and Medical Genetics . 2014.Volume 7 - Number 2
22. Clinical features and therapeutic outcome of 30 patients diagnosed with primary myelofibrosis at the national center of hematology. J Fac Med Baghdad 2014; Vol.56, No .4
23. Assessment of Plasma FXII:C in pregnant women with severe preeclampsia. Mustansiriyah Medical Journal Volume 14 Issue 1 June 2015
24. DETECTION OF HUMAN HERPESVIRUS 6 IN PATIENT WITH ACUTE MYELOID LEUKEMIA IN BAGHDAD-IRAQ. Int. J. Science Nature, VOL.6 (3) 2015: 484-487
25. Assessment of side effects of venesection (phlebotomy) procedure in Iraqi patients presenting with erythrocytosis: single center experience. IJH.2015;vol 4. No.1: pp 61-66
26. C- Reactive protein and iron status in Iraqi patients with acute myeloid leukemia before and after treatment. IJH 2015; vol 4.no.1: pp 101-118
27. Association of human herpesvirus 6 with lymphoid malignancies in Iraqi patients. IJH 2015; vol 4,no.2 : 18-29
28. Inducing of interleukins-10 and 8 by Epstein BarrVirus in chronic lymphocytic leukemia. IJH. Vol 5, issue1 , May 2016
29. Types of anemia in patients with rheumatoid arthritis in Sulaymaniyah-Kurdistan region of Iraq . IJH. Vol 5 , issue 1 , May 2016
30. Assessment of Biochemical and Molecular Biomarkers for Diagnosis\Prognosis of Chronic Lymphocytic Leukemia in Iraqi Patients. International Journal of Science and Research (IJSR).Volume 5 Issue 6, June 2016
31. Estimation of ZAP-70, interleukin 6 nd interleukin 10 levels in sera of Iraqi newly diagnosed CLL . IJH 2016 .vol 5 issue 2
32. Evaluation of the Effects of Nilotinib on Platelet Function in Patients with Chronic Myeloid Leukemia in Chronic Phase. BRITISH JOURNAL OF HAEMATOLOGY 181, 195-196 2018
33. Effects of Nilotinib on Platelet Function in Patients with Chronic Myeloid Leukemia in Chronic Phase. Leukemia Research Reports 2018
34. On the use of substandard medicines in hematology: An emerging concern in the Middle East and North Africa region. European journal of internal medicine 48, e40-e41 2018
35. Assessment of cardiac function in patients with chronic myeloid leukemia treated with imatinib at the national center of hematology. Asian Journal of Pharmaceutical and Clinical Research, Vol. 11, no. 10, Oct. 2018, pp. 118-20, doi:10.22159/ajpcr.2018.v11i10.27059
36. Assessment of Clinical Outcome of Patients With Primary Myelofibrosis Treated With Ruxolitinib in the Real-World Practice. Global Journal of

Health Science; Vol. 11, No. 6; 2019. ISSN 1916-9736 E-ISSN 1916-9744.  
Published by Canadian Center of Science and Education

37. Lipid profile in leukemia and non-Hodgkin lymphoma patients. *Indian journal of public health research and development*.02/2019;10(22):634
38. Challenges associated with limited-resources cancer care facility: Bilateral breast myeloid sarcoma as an example. *Clin Case Rep*. 2019 Nov; 7(11): 2022–2026.
39. Comparison between WBC, RBC, and HB levels for Iraqi AML patients pre and post 3 and 7 treatment within four age groups segmented based on growth levels. *Indian journal of public health research and development*. 02/2020. Vol 11 no. :02-03
40. Mutation evaluation in P53 exon 5 in Iraqi AML patients with 4 growth levels. *Indian Journal of Forensic Medicine & Toxicology*, January-March 2020, Vol. 14, No. 1, pages 697-702. DOI 10.37506/v14/i1/2020/ijfmt/192984
41. The Effects of Smoking on IgE, Oxidative Stress and Haemoglobin Concentration. *Asian Pac J Cancer Prevention*. 2020 Apr 1;21(4):1069-1072. doi: 10.31557/APJCP.2020.21.4.1069.
42. The concentration and type of monoclonal protein and their impact on clinical severity in patients with symptomatic myeloma. *Journal of Kurdistan board of medical specialities*. 2020. Vol. 7 no.1
43. Bone marrow necrosis in a patient with advanced Hodgkin's lymphoma after G-CSF and Plerixafor treatment during harvesting for autologous bone marrow transplantation: is it possible?. DOI: 10.1016/j.htct.2020.03.005